Skip to search formSkip to main contentSkip to account menu

Pegaptanib Sodium

Known as: Pegaptanib Octasodium 
The sodium salt form of pegaptanib, a 28-mer RNA aptamer covalently linked to two branched 20-kD polyethylene glycol (PEG) chains, with anti… 
National Institutes of Health

Related topics

Related topics

5 relations
0.09 ML pegaptanib 3.33 MG/ML Prefilled Syringe [Macugen]NX1838

Narrower (2)

EYE 001Macugen

Broader (1)

pegaptanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.
Highly Cited
2010
Highly Cited
2010
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.
OBJECTIVE To examine associations between therapies for age-related macular degeneration and risks of all-cause mortality… 
Highly Cited
2009
Highly Cited
2009
Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy
Background: To compare the efficacy of intravitreal pegaptanib (IVP) with panretinal laser photocoagulation (PRP) in the… 
Highly Cited
2009
Highly Cited
2009
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
OBJECTIVES To assess the safety and efficacy of intravitreous pegaptanib sodium for the treatment of macular edema following… 
Highly Cited
2007
Highly Cited
2007
Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium
PurposeThe purpose was to report a case of elevated intraocular vascular endothelial growth factor (VEGF) levels in a 2-year-old… 
Highly Cited
2007
Highly Cited
2007
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
Highly Cited
2007
Highly Cited
2007
A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
Highly Cited
2006
Highly Cited
2006
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.
Review
2006
Review
2006
Anti‐VEGF Aptamer (Pegaptanib) Therapy for Ocular Vascular Diseases
Abstract:  Vascular endothelial growth factor (VEGF) is a central regulator of both physiological and pathological angiogenesis… 
Highly Cited
2005
Highly Cited
2005
ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUM: An Exploratory Analysis
Purpose: To assess the vision benefit of treating early subfoveal choroidal neovascularization secondary to age-related macular… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)